Lotte Biologics said Tuesday it will present research results on its antibody-drug conjugate, or ADC, platform technology, SoluFlex Link, at the American Association for Cancer Research meeting, AACR 2026, to be held April 17-22 in San Diego.
At the conference, the company will disclose results from an evaluation of the structural stability of an ADC using SoluFlex Link technology co-developed with Kanaph Therapeutics.
According to Lotte Biologics, an analysis of aggregate changes over time found that a control group without the SoluFlex linker showed increasing aggregation as time passed, while the group using the SoluFlex linker showed markedly suppressed aggregation and maintained high stability. The company said the technology could help keep product quality stable during distribution and storage.
In cell tests targeting multiple markers, including epidermal growth factor receptor (EGFR) and trophoblast cell surface antigen 2 (TROP-2), the SoluFlex Link group showed stronger anticancer effects at lower concentrations than the non-applied group, the company said. It also showed strong efficacy in triple-negative breast cancer cells.
Lotte Biologics said animal studies showed improved in vivo pharmacokinetics, or PK, based on high stability. The company said the findings support SoluFlex Link as a platform technology not limited to a specific antibody, with potential to improve anticancer efficacy and pharmacokinetic properties.
A Lotte Biologics official said SoluFlex Link is a differentiated platform that goes beyond the limits of existing technologies, adding that the company will provide solutions to help partners and customers develop next-generation ADCs.
AACR is considered one of the world’s three major cancer meetings, along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). It brings together cancer researchers and industry representatives to discuss cancer treatments and new drug development.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.